The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients

Jacqueline G. O'Leary, Millie Samaniego, Marta Crespo Barrio, Luciano Potena, Adriana Zeevi, Arjang Djamali, Emanuele Cozzi

Research output: Contribution to journalReview article

52 Citations (Scopus)

Abstract

Production of de novo donor-specific antibodies (dnDSA) is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all solid organ transplantation. In this article, we review the data available on the risk of individual immunosuppressive agents and their ability to prevent dnDSA production. Induction therapy with rabbit antithymocyte globulin may achieve a short-Term decrease in dnDSA production in moderately sensitized patients. Rituximab induction may be beneficial in sensitized patients, and in abrogating rebound antibody response in patients undergoing desensitization or treatment for antibody-mediated rejection. Use of bortezomib for induction therapy in at-risk patients is of interest, but the benefits are unproven. In maintenance regimens, nonadherent and previously sensitized patients are not suitable for aggressive weaning protocols, particularly early calcineurin inhibitor withdrawal without lymphocyte-depleting induction. Early conversion to mammalian target of rapamycin inhibitor monotherapy has been reported to increase the risk of dnDSA formation, but a combination of mammalian target of rapamycin inhibitor and reduced-exposure calcineurin inhibitor does not appear to alter the risk. Early steroid therapy withdrawal in standard-risk patients after induction has no known dnDSA penalty. The available data do not demonstrate a consistent effect of mycophenolic acid on dnDSA production. Risk minimization for dnDSA requires monitoring of adherence, appropriate risk stratification, risk-based immunosuppression intensity, and prospective DSA surveillance.

Original languageEnglish (US)
Pages (from-to)39-53
Number of pages15
JournalTransplantation
Volume100
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Immunosuppressive Agents
Antibody Formation
Tissue Donors
Transplants
Antibodies
Sirolimus
Mycophenolic Acid
Antilymphocyte Serum
Transplant Recipients
Graft Rejection
Organ Transplantation
Secondary Prevention
Weaning
Immunosuppression
Therapeutics
Steroids
Maintenance
Lymphocytes
Rabbits

ASJC Scopus subject areas

  • Transplantation

Cite this

The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients. / O'Leary, Jacqueline G.; Samaniego, Millie; Barrio, Marta Crespo; Potena, Luciano; Zeevi, Adriana; Djamali, Arjang; Cozzi, Emanuele.

In: Transplantation, Vol. 100, No. 1, 01.01.2016, p. 39-53.

Research output: Contribution to journalReview article

O'Leary, Jacqueline G. ; Samaniego, Millie ; Barrio, Marta Crespo ; Potena, Luciano ; Zeevi, Adriana ; Djamali, Arjang ; Cozzi, Emanuele. / The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients. In: Transplantation. 2016 ; Vol. 100, No. 1. pp. 39-53.
@article{83cff081beba4f9abbd9f3b43a583511,
title = "The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients",
abstract = "Production of de novo donor-specific antibodies (dnDSA) is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all solid organ transplantation. In this article, we review the data available on the risk of individual immunosuppressive agents and their ability to prevent dnDSA production. Induction therapy with rabbit antithymocyte globulin may achieve a short-Term decrease in dnDSA production in moderately sensitized patients. Rituximab induction may be beneficial in sensitized patients, and in abrogating rebound antibody response in patients undergoing desensitization or treatment for antibody-mediated rejection. Use of bortezomib for induction therapy in at-risk patients is of interest, but the benefits are unproven. In maintenance regimens, nonadherent and previously sensitized patients are not suitable for aggressive weaning protocols, particularly early calcineurin inhibitor withdrawal without lymphocyte-depleting induction. Early conversion to mammalian target of rapamycin inhibitor monotherapy has been reported to increase the risk of dnDSA formation, but a combination of mammalian target of rapamycin inhibitor and reduced-exposure calcineurin inhibitor does not appear to alter the risk. Early steroid therapy withdrawal in standard-risk patients after induction has no known dnDSA penalty. The available data do not demonstrate a consistent effect of mycophenolic acid on dnDSA production. Risk minimization for dnDSA requires monitoring of adherence, appropriate risk stratification, risk-based immunosuppression intensity, and prospective DSA surveillance.",
author = "O'Leary, {Jacqueline G.} and Millie Samaniego and Barrio, {Marta Crespo} and Luciano Potena and Adriana Zeevi and Arjang Djamali and Emanuele Cozzi",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/TP.0000000000000869",
language = "English (US)",
volume = "100",
pages = "39--53",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients

AU - O'Leary, Jacqueline G.

AU - Samaniego, Millie

AU - Barrio, Marta Crespo

AU - Potena, Luciano

AU - Zeevi, Adriana

AU - Djamali, Arjang

AU - Cozzi, Emanuele

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Production of de novo donor-specific antibodies (dnDSA) is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all solid organ transplantation. In this article, we review the data available on the risk of individual immunosuppressive agents and their ability to prevent dnDSA production. Induction therapy with rabbit antithymocyte globulin may achieve a short-Term decrease in dnDSA production in moderately sensitized patients. Rituximab induction may be beneficial in sensitized patients, and in abrogating rebound antibody response in patients undergoing desensitization or treatment for antibody-mediated rejection. Use of bortezomib for induction therapy in at-risk patients is of interest, but the benefits are unproven. In maintenance regimens, nonadherent and previously sensitized patients are not suitable for aggressive weaning protocols, particularly early calcineurin inhibitor withdrawal without lymphocyte-depleting induction. Early conversion to mammalian target of rapamycin inhibitor monotherapy has been reported to increase the risk of dnDSA formation, but a combination of mammalian target of rapamycin inhibitor and reduced-exposure calcineurin inhibitor does not appear to alter the risk. Early steroid therapy withdrawal in standard-risk patients after induction has no known dnDSA penalty. The available data do not demonstrate a consistent effect of mycophenolic acid on dnDSA production. Risk minimization for dnDSA requires monitoring of adherence, appropriate risk stratification, risk-based immunosuppression intensity, and prospective DSA surveillance.

AB - Production of de novo donor-specific antibodies (dnDSA) is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all solid organ transplantation. In this article, we review the data available on the risk of individual immunosuppressive agents and their ability to prevent dnDSA production. Induction therapy with rabbit antithymocyte globulin may achieve a short-Term decrease in dnDSA production in moderately sensitized patients. Rituximab induction may be beneficial in sensitized patients, and in abrogating rebound antibody response in patients undergoing desensitization or treatment for antibody-mediated rejection. Use of bortezomib for induction therapy in at-risk patients is of interest, but the benefits are unproven. In maintenance regimens, nonadherent and previously sensitized patients are not suitable for aggressive weaning protocols, particularly early calcineurin inhibitor withdrawal without lymphocyte-depleting induction. Early conversion to mammalian target of rapamycin inhibitor monotherapy has been reported to increase the risk of dnDSA formation, but a combination of mammalian target of rapamycin inhibitor and reduced-exposure calcineurin inhibitor does not appear to alter the risk. Early steroid therapy withdrawal in standard-risk patients after induction has no known dnDSA penalty. The available data do not demonstrate a consistent effect of mycophenolic acid on dnDSA production. Risk minimization for dnDSA requires monitoring of adherence, appropriate risk stratification, risk-based immunosuppression intensity, and prospective DSA surveillance.

UR - http://www.scopus.com/inward/record.url?scp=84952334199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952334199&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000000869

DO - 10.1097/TP.0000000000000869

M3 - Review article

C2 - 26680372

AN - SCOPUS:84952334199

VL - 100

SP - 39

EP - 53

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -